Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C

Table 2

Virologic response by patient subgroups.

Patient group	N (%)				P (generic versus SOVALDI)
	Generic sofosbuvir		SOVALDI
	All patients	Patients with SVR data	All patients	Patients with SVR data	All patients	Patients with SVR data
Overall SVR	N=29	N=25	N=37	N=31
	21 (72.4)	21 (84)	28 (75.7)	28 (90.3)	0.78	0.69
Excluding decompensated cirrhotics	N=24	N=21	N=22	N=20
	18 (75)	18 (85.7)	20 (90.9)	20 (100)	0.25	0.23
Genotype 3	N=26	N=23	N=23	N=17
	19 (73.1)	19 (82.6)	14 (60.9)	14 (82.4)	0.54	1.0
Compensated cirrhotics	N=15	N=13	N=10	N=9
	10 (66.7)	10 (76.9)	9 (90)	9 (100)	0.34	0.24
Treatment experienced	N=5	N=5	N=8	N=5	1.0	0.44
	3 (60)	3 (60)	5 (62.5)	5 (100)

SVR: sustained virologic response.